GlassScriptPhysician profile
Ha T Le
NPI 1144491143
$11,109.80
in general payments reported to CMS, 2019-2025
34 companies · $3,292 in 2025
The $3,292 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,735 · 2022: $1,741 · 2023: $2,046 · 2024: $2,297 · 2025: $3,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,215 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,214.69 |
| Education | $419.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,667.30 | 2021-2025 | Freestyle Libre 2, Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $1,214.60 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $938.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $904.32 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $706.62 | 2021-2025 | Repatha, Otezla, Otezla |
| Intra-Sana Laboratories | $517.71 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.06 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $458.20 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $420.10 | 2021-2025 | |
| Lucid Diagnostics INC. | $341.89 | 2022-2024 | |
| Dexcom, INC. | $317.64 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $313.06 | 2022-2025 | |
| Boston Scientific Corporation | $300.26 | 2021-2024 | |
| Daiichi Sankyo INC. | $299.22 | 2022-2025 | Injectafer |
| Pfizer INC. | $280.31 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $278.62 | 2024-2025 | Voquezna |
| Horizon Therapeutics Plc | $269.30 | 2022-2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $261.44 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.90 | 2022 | |
| Exact Sciences Corporation | $147.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $143.59 | 2025 | Symbravo |
| Nevro Corp. | $138.29 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $81.34 | 2021-2022 | |
| Tactile Systems Technology INC | $78.28 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Idorsia Pharmaceuticals US INC | $55.56 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $43.82 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $43.20 | 2023-2024 | Arexvy, Shingrix |
| Genentech USA, INC. | $37.73 | 2021-2022 | |
| Smith+Nephew, INC. | $32.93 | 2025 | Collagenase Santyl |
| C. R. Bard, INC. & Subsidiaries | $28.96 | 2023 | Bd Onclarity |
| Amarin Pharma, INC. | $19.57 | 2021 | |
| Astellas Pharma US INC | $18.78 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $18.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.91 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.